A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Recruiting

Phase 2

NanO2™ & RadiationA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

Sponsor:

NuvOx LLC

Code:

NCT03862430

Conditions

Glioblastoma Multiforme

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NanO2TM

Placebo Saline Infusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by NuvOx LLC on 2025-01-31.